Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis by Di Paola, R et al.
fphar-07-00382 October 12, 2016 Time: 11:18 # 1
ORIGINAL RESEARCH
published: 14 October 2016
doi: 10.3389/fphar.2016.00382
Edited by:
Filippo Caraci,
University of Catania, Italy
Reviewed by:
Raffaele Capasso,
University of Naples Federico II, Italy
Letteria Minutoli,
University of Messina, Italy
*Correspondence:
Salvatore Cuzzocrea
salvator@unime.it.
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 11 August 2016
Accepted: 03 October 2016
Published: 14 October 2016
Citation:
Di Paola R, Fusco R, Gugliandolo E,
Crupi R, Evangelista M, Granese R
and Cuzzocrea S (2016)
Co-micronized
Palmitoylethanolamide/Polydatin
Treatment Causes Endometriotic
Lesion Regression in a Rodent Model
of Surgically Induced Endometriosis.
Front. Pharmacol. 7:382.
doi: 10.3389/fphar.2016.00382
Co-micronized
Palmitoylethanolamide/Polydatin
Treatment Causes Endometriotic
Lesion Regression in a Rodent Model
of Surgically Induced Endometriosis
Rosanna Di Paola1, Roberta Fusco1, Enrico Gugliandolo1, Rosalia Crupi1,
Maurizio Evangelista2, Roberta Granese3 and Salvatore Cuzzocrea1,4*
1 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy,
2 Institute of Anaesthesiology and Reanimation, Catholic University of the Sacred Heart, Rome, Italy, 3 Department of Human
Pathology, University of Messina, Messina, Italy, 4 Department of Pharmacological and Physiological Science, Saint Louis
University, Saint Louis, MO, USA
Endometriosis is a chronic, painful disease characterized by the presence of endometrial
glands and stroma outside the uterine cavity. Palmitoylethanolamide (PEA), an
endogenous fatty acid amide, has anti-inflammatory and neuroprotective effects. PEA
lacks free radical scavenging activity, unlike polydatin (PLD), a natural precursor of
resveratrol. The aim of this study was to investigate the effect of orally administered
co-micronized PEA/polydatin [m(PEA/PLD)] in an autologous rat model of surgically
induced endometriosis. Endometriosis was induced in female Wistar albino rats by
auto-transplantation of uterine squares (implants) into the intestinal mesentery and
peritoneal cavity. Rats were distributed into one control group and one treatment
group (10 animals each): m(PEA/PLD) 10 mg/kg/day. At 28 days after surgery the
relative volume of the endometrioma was determined. Endometrial-like tissue was
confirmed by histology: Masson trichrome and toluidine blue were used to detect
fibrosis and mast cells, respectively. The treated group displayed a smaller cyst
diameter, with improved fibrosis score and mast cell number decrease. m(PEA/PLD)
administration decreased angiogenesis (vascular endothelial growth factor), nerve
growth factor, intercellular adhesion molecule, matrix metalloproteinase 9 expression,
and lymphocyte accumulation. m(PEA/PLD) treatment also reduced peroxynitrite
formation, (poly-ADP)ribose polymerase activation, IkBα phosphorylation and nuclear
facor-kB traslocation in the nucleus. Our results suggested that m(PEA/PLD) may be of
use to inhibit development of endometriotic lesions in rats.
Keywords: endometriosis, palmitoylethanolamide, polydatin, rat, treatment
Abbreviations: H&E, Hematoxylin/eosin; HCl, hydrochloric acid; ICAM, intracellular adhesion molecule; m(PEA/PLD),
co-micronized PEA/polydatin; MPO, myeloperoxidase; NaCl, sodium chloride; NGF, nerve growth factor; PAR, (poly-
ADP)ribose polymerase activation; PEA, palmitoylethanolamide; PLD, polydatin; ROS, reactive oxygen species.
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INTRODUCTION
Endometriosis is a painful chronic disease characterized by the
presence of endometrial glands and stroma outside the uterine
cavity, predominantly, in the pelvic compartment. It affects∼5%
(Vigano et al., 2004) of women in reproductive age and it is
associated with pelvic pain and infertility (Giudice, 2010). It
has a multifactorial etiology including hormonal, genetic, and
immunological aspects. The exact mechanism of the pathology is
still undefined; The most widely accepted theory, the retrograde
menstruation theory, was proposed by Sampson (1927). It
postulates that epithelial cells and endometrial stroma regurgitate
outside the fallopian tubes during menstruation. Subsequently,
they will implant and grow into peritoneum and ovary due to a
pressure gradient probably from dyssynergic uterine contraction
(Groothuis et al., 2005). Other theories on the endometriosis
pathogenesis include the endometrial steam cell implantation
(an expansion of the Sampson theory), immune dysfunction
and Mullerian remnant abnormalities (Burney and Giudice,
2012). The disease has a genetic etiology, with a hereditability
of ∼51% (Nyholt et al., 2012). Seven risk loci manifested a
robust association with endometriosis (Pagliardini et al., 2013).
There is a significant overlap in polygenic risk for endometriosis
between the European and Japanese GWA cohorts (Nyholt et al.,
2012). In addition, endometriosis is considered an estrogen-
dependent disorder. An alteration of estrogens signaling are
present in the ectopic tissue of patients affected by disease;
in particular elevated expression of Extrogen receptor β is
predicted to play a role in the development of endometriosis;
probably, it contributes to the resistance to progesterone action
in some of patients suffering from endometriosis (Bulun et al.,
2012).
American Society of Reproductive Medicine report that
“Unfortunately, there is no permanent cure for this condition,
so it often requires a life-long management plan with the goal of
maximizing the use of medical treatment and avoiding repeated
surgical procedures” (Practice Committee of American Society
for Reproductive Medicine, 2008). For this reason it is important
to evaluate the efficacy or the long-term safety and tolerability of
the medical options available, represented by hormonal therapies.
Recent evidence suggest to use an alternative non-hormonal
drugs, efficacious as hormonal drugs, but with less systemic side
effects.
Current knowledge on the pathophysiology of endometriosis
indicates that induction of the disease involves changes in
structural elements, a proinflammatory environment, resistance
to apoptosis, and increased angiogenesis (Gauché-Cazalis
et al., 2012). Palmitoylethanolamide, an endogenous fatty
acid amide, has shown in numerous studies significant anti-
inflammatory, and analgesic effects in experimental models of
chronic and acute neuropathic pain and chronic inflammation
(De Filippis et al., 2011), and in treating pathological pain
clinically (Skaper et al., 2013). PEA down-regulates mast cell
activation and inhibits their degranulation and has recently
been reported to reduce viscerovisceral hyperalgesia in a rat
model of endometriosis plus ureteral calculus (Iuvone et al.,
2016).
However, the PEA does not have antioxidant effects, for
this reason it was used a compound that combines the anti-
inflammatory action of the PEA to the antioxidant action
of 3,4′,5-trihydroxystibene-3-β-mono-D-glycoside (polydatin), a
natural glucoside of resveratrol.
It has been demonstrated that PLD protects organs like brain,
lung, intestine, and heart against ischemia–reperfusion injury
(Miao et al., 2011), and possesses anti-oxidation (Kerem et al.,
2006), anti-shock, and anti-inflammatory (Lanzilli et al., 2012)
properties. Polydatin also inhibits migration and proliferation
of vascular endothelial cells and inhibits the angiogenic
process via inhibition of proangiogenic factors such as matrix
metalloproteinases (MMPs) and vascular endothelial growth
factor (VEGF).
The purpose of this study was to investigate whether oral
administration of m(PEA/PLD) could reduce inflammation and
pain associated with endometriosis.
MATERIALS AND METHODS
Animals
Sprague–Dawley female rats (200–230 g, Harlan, Nossan, Italy)
were used throughout. They received food and water ad libitum.
The study was authorized by the University of Messina Review
Board for the care of animals (Protocol number 8/U-apr16).
Animal care followed Italian (D.M.116192) and EEC (O.J. of E.C.
L 358/1 12/18/1986) regulations on protection of animals used for
experimental and scientific purposes.
Induction of Experimental Endometriosis
Endometriosis was induced using homologous uterine horn
transplantation. All rats were anesthetized with Isoflurane. As
described by Rajkumar et al. (1990) laparotomy was performed,
the uterus was exposed and the left horn excised. This tissue
fragment was placed in phosphate-buffered saline (PBS) 37◦C
and was cut along the longitudinal axis, obtaining two pieces
of 5 × 5 mm. One of the two squares was sutured to the
inner surface of the abdominal wall, with the endometrial
layer facing a large vessel in the peritoneal cavity, and the
other one to the bowel mesentery close to a large vessel.
All implants were sutured using a sterile 6-0 silk suture
and the abdominal cavity was closed using 4-0 silk suture.
Penicillin (40,000 U/kg) was administered for 5 days after the
surgery.
Experimental Groups
Rats were randomized with the technique of “simple
randomization” (Ivers et al., 2012) and divided into the
following groups (N = 10).
Control Group
Rats were subjected to experimental endometriosis as described
above, and vehicle (carboxymethylcellulose 1.5% w/v in saline)
was administered orally by gavage, on the 14 day and for the next
14 days.
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m(PEA/PLD) Group
Rats were subjected to experimental endometriosis as
described above, and m(PEA/PLD) (10 mg/kg) dissolved in
carboxymethylcellulose (1.5% w/v in saline) was administered
orally by gavage, on the 14 day and for the next 14 days.
The dose of m(PEA/PLD) was based on a previous study
(Esposito et al., 2016).
In order to evaluate endometriotic lesions, rats were sacrificed
at 28 days after endometriosis induction (Ricci et al., 2013; Ozcan
Cenksoy et al., 2015). Rats were anesthetized with isoflurane;
laparotomy was performed to collect the endometriotic implants.
Implants were excised from both groups, weighed, measured, and
processed for histology and biochemical studies.
Histology
For histopathological investigations, endometriotic implants
were collected 28 days post-surgery. Samples were fixed at room
temperature in buffered formaldehyde solution (10% in PBS) for
24 h, then dehydrated using a graded series of ethanol, embedded
in Paraplast (Sherwood Medical, Mahwah, NJ, USA) and cut
into 7-mm thick sections. Sections were deparaffinized with
xylene, stained with H&E and analyzed using an Axiovision Zeiss
(Milan, Italy) microscope. Damage was estimated by an expert
histopathologist blinded to the study, and scored as follows:
0 = no implantation, 1 = cellular infiltration, 2 = edema,
3 = continuous inflammatory lesions, 4 = presence of glandular
epithelium, and stroma.
Masson Trichrome and Toluidine Blue
Staining
To evaluate the degree of fibrosis, explant tissue sections were
stained with Masson trichrome according to the manufacturer’s
protocol (Bio-Optica, Milan, Italy). For evaluation of number
and degranulation of mast cells, tissue sections were stained
with toluidine blue. Sections were deparaffinized in xylene and
dehydrated through a graded series of ethanol, 5 min in each
solution. The sections were next placed in water for 5 min,
transferred to toluidine blue for 4 min and then blotted carefully.
Sections were placed in absolute alcohol for 1 min, cleared in
xylene, and mounted on a glass slide using Eukitt (Bio-Optica,
Milan, Italy). Sections were stained blue and the mast cells
were stained purple. Metachromatically stained mast cells were
enumerated by counting five high-power fields (40×) per section
using Axiovision Zeiss (Milan, Italy) microscope.
Immunohistochemical Localization of
Nitrotyrosine, poly(ADP-Ribose) (PAR),
VEGF, NGF, MMP9, MPO, and ICAM
At 28 days from surgery, endometriotic implants were fixed in
10% (w/v) PBS-buffered formaldehyde and embedded in paraffin.
Seven micrometer sections were prepared from tissues. After
deparaffinization, endogenous peroxidase was quenched with
0.3% (v/v) hydrogen peroxide in 60% (v/v) water for 30 min.
The slides were permeabilized with 0.1% (w/v) Triton X-100
in PBS for 20 min. Tissue sections were incubated in 2%
(v/v) normal goat serum in PBS to block non-specific binding.
Sequential incubation for 15 min with avidin and biotin (Vector
Laboratories, Burlingame, CA, USA) was performed to block,
respectively, endogenous avidin, or biotin binding sites. Sections
were then incubated overnight with: anti-PAR antibody (H-
250: sc-7150, 1: 550 in PBS, Santa Cruz Biotechnology), anti-
nitrotyrosine antibody (Millipore, 06-284), anti-VEGF antibody
(A-20: sc-152, 1:300 in PBS, Santa Cruz Biotechnology), anti-
NGF antibody (E-12: sc-365944, 1:450 in PBS, Santa Cruz
Biotechnology), anti-MMP9 antibody (C-20: sc-6840, 1:350 in
PBS, Santa Cruz Biotechnology), anti-MPO antibody (2C7:
sc-59600, 1:325 in PBS, Santa Cruz Biotechnology), or anti-
ICAM antibody (G-5: sc-8439, 1:325 in PBS, Santa Cruz
Biotechnology). Samples were washed with PBS, and incubated
with secondary antibody. Specific labeling was identified with
a biotin-conjugated goat anti-rabbit IgG and avidin–biotin
peroxidase complex (Vector Laboratories, Burlingame, CA,
USA). Immunohistochemical images were collected using a
Zeiss microscope and Axio Vision software. For graphic display
of densitometric analyses, the intensity of positive staining
(brown staining) was measured by computer-assisted color
image analysis (Leica QWin V3, UK). The percentage area
of immunoreactivity (determined by the number of positive
pixels) was expressed as percent of total tissue area (red
staining).
Western Blot Analysis for Nitrotyrosine,
VEGF, NGF, ICAM, IkB-α, and NF-kB
Endometriotic explants were suspended in buffer A (0.2 mM
phenylmethylsulfonyl fluoride, 0.15 µM pepstatin A, 20 µM
leupeptin, and 1 mM sodium orthovanadate) homogenized for
2 min, and centrifuged at 10000 g for 10 min at 4◦C. Supernatants
represented the cytosolic fraction. The pellets, containing nuclei,
were re-suspended in buffer B (150 mM NaCl, 1% Triton
X-100, 1 mM EGTA, 1 mM EDTA, 10 mM Tris–HCl pH
7.4, 0.2 mM phenylmethylsulfonyl fluoride, 20 µM leupeptin,
and 0.2 mM sodium orthovanadate). After centrifugation for
30 min at 15,000 g at 4◦C, the supernatants contained nuclear
proteins. Samples were stored at −80◦C for further analysis.
The levels of nitrotyrosine, VEGF, NGF, ICAM, IkB-α, and
Bax were quantified in the cytosolic fraction, while the nuclear
fraction was used to quantify NF-kB p65 levels. Membranes
were blocked with 1× PBS, 5% (w/v) non-fat dried milk for
40 min at room temperature and later probed with one of
the following primary antibodies: anti-nitrotyrosine (Millipore,
06-284), anti-VEGF (A-20: sc-152, 1:300 in PBS, Santa Cruz
Biotechnology), anti-NGF (Santa Cruz Biotechnology, E-12: sc-
365944, 1:450 in PBS, v/v) or anti-ICAM antibody (G-5: sc-
8439, 1:325 in PBS, Santa Cruz Biotechnology), anti-Bax (P-
19: sc-526, 1:225 in PBS, Santa Cruz Biotechnology), IkB-α
(1:500, Santa Cruz Biotechnology) or, anti-NF-kB p65 (1:400;
Santa Cruz Biotechnology) in 1× PBS, 5% (w/v) non-fat dried
milk, 0.1% Tween-20 at 4◦C overnight. Filters were incubated
with peroxidase-conjugated bovine anti-mouse IgG secondary
antibody or peroxidase-conjugated goat anti-rabbit IgG (1:5000,
Jackson ImmunoResearch, West Grove, PA, USA) for 1 h
at room temperature. To establish that blots contained equal
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amounts of protein they were also incubated with an antibody
against β-actin (1:500, Sigma–Aldrich). Relative expression of
protein bands for nitrotyrosine (67 kDa), VEGF (34 kDa),
NGF (13 kDa), ICAM (90 kDa), IkB-α (37 kDa), NF-kB p65
(65 kDa), and Bax (23 kDa) was quantified by densitometric
scanning of the X-ray films with GS-700 Imaging Densitometer
(GS-700, Bio-Rad Laboratories, Milan, Italy) and a Image
Lab 3.0 software (Bio-Rad, USA), and standardized to β-actin
levels.
Quantification of Pain Behaviors
Uterine Pain Behaviors
Uterine pain behaviors were evaluated looking at four positions:
“lambda” position (the rat suddenly hunches its back upward
into a sharp angle to forma triangular shape relative to the
floor), “alpha” position (rat with abdomen adherent to the
floor and nose curving toward the tail of the affected side),
“stretch-flat” position, with stretching of the body with abdomen
adherent to the floor, and “squash-pelvic” position (squashing
of the lower part of the abdomen to the floor while in a
standing or sitting position). For each rat, relative to the
whole period of recording, the uterine pain behaviors are
characterized in terms of global duration of uterine positions
(sum of duration of all positions; Giamberardino et al.,
2002).
The Tail-Fick Method
The warm water tail-flick test was used to determine pain
threshold. Test was conducted before and during treatment.
4 cm of the rat-tail was placed in 50 ± 0.5◦C warm water
and the time between tail input and withdrawal from the
water was recorded (three tests were conducted and the average
in units of seconds was recorded). The latency was recorded
with a sensitivity of 0.01 s. To perform a measurement, the
rat had to remain calm, without unconditional unexpected
movements of the tail. A maximum tail-flick latency of 10 s
was used to minimize tissue damage to the tail (Liu et al.,
2012).
The Hot-Plate Method
The hot-plate latency was assessed by placing the rat on a metal
surface maintained at 53.6◦C (Hot Plate, Ugo Basile, Milan, Italy).
The rat was observed closely during the measurement period and
the licking of a hind paw was taken as the end point. At this
moment the latency to respond was recorded and the rat was
immediately removed. Maximal latency accepted was 45 s (Liu
et al., 2012).
Materials
Co-micronized Palmitoylethanolamide/Polydatin was obtained
from Epitech Group SpA (Saccolongo, Italy). All compounds
were obtained from Sigma-Aldrich (Milan, Italy). All chemicals
were of the highest commercial grade available. All stock
solutions were prepared in non-pyrogenic saline (0.9% NaCl;
Baxter, Italy, UK).
Statistical Evaluation
All values are expressed as mean ± standard error of the mean
(SEM) of N observations. For in vivo studies N represents
the number of animals used. For histological experiments, the
figures shown are representative of at least three experiments
(histological staining) performed on different days on tissue
sections collected from all animals in each group. The results
were analyzed by 2-way ANOVA. A P-value of less than 0.05 was
considered significant.
RESULTS
Effects of m(PEA/PLD) Treatment on the
Degree of Endometriosis
At 28 days post-surgery all uterine implants displayed transparent
cystic areas. Both control (Figure 1A) and m(PEA/PLD)
(Figure 1B) groups developed cysts in the mesentery and
abdominal wall. The two groups did not differ in cysts
number, although cyst size was smaller in m(PEA/PLD)-
treated rats compared to control rats (P < 0.05; Figure 1C).
Histological examination showed the presence of endometrial
tissue containing glandular epithelium and stroma. Cysts
in the control group were characterized by an intense
cellular infiltration, edema and continuous inflammatory lesions
(Figure 1D, see histological injury score in panel 1F).
m(PEA/PLD) treatment reduced the level and severity of the
macroscopic and histological marks of endometriotic cysts
(Figure 1E, see histological injury score in Figure 1F).
Effects of m(PEA/PLD) Treatment on
Fibrosis and MMP9 Expression
In endometriotic lesions 28 days post-implantation the degree of
fibrosis, assessed by Masson trichrome staining (Figures 2A,B)
demonstrated a fibrotic area stained blue that was larger in the
m(PEA/PLD) group (Figures 2B,C) than in the control group.
Moreover, immunohistochemical analysis showed a significantly
increased MMP9 expression (a marker of inflammation,
especially in infiltration of inflamed tissues) in endometriotic
tissues from control rats (Figures 2D,F), whereas m(PEA/PLD;
10 mg/kg) reduced the degree of positive staining for MMP9
(Figures 2E,F).
Effects of m(PEA/PLD) Treatment on
Mast Cells Fensity and NGF Expression
Mast cells numbers in endometriotic tissues were evaluated
by staining with toluidine blue (Figures 3A,C). Compared
with the control group, the number of mast cells in the
m(PEA/PLD) group was significantly reduced (Figures 3B,C).
There is evidence to suggest that NGF can trigger mast cell
degranulation (Lin et al., 2015). Immunostaining for NGF was
significantly increased in endometriotic tissues from control
rats (Figures 3D,F), whereas m(PEA/PLD; 10 mg/kg) reduced
such positive staining (Figures 3E,F). NGF expression in
endometriotic explants from control rats was also increased
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FIGURE 1 | Effect of m(PEA/PLD) treatment on cyst diameter and histological damage score. m(PEA/PLD) treatment significantly reduced cyst size
(0.46 mm) (B,C) when compared with vehicle-treated control rats (1.0 mm) (A,C) (◦p = 0.01). Histological examination showed the presence of endometrial tissue
containing glandular epithelium and stroma. Cysts of the control group contained cellular infiltration and edema (4) (D,F), and m(PEA/PLD) reduced the severity of
histological marks of endometriotic cysts (1.33) (E,F) (◦p = 0.01). Data are means ± SD of 10 rats for each group. ◦P < 0.05 vs. vehicle group.
by Western blot analysis, and was reduced by m(PEA/PLD)
treatment (Figures 3G,H).
Effects of m(PEA/PLD) Treatment on
VEGF, ICAM, and MPO Expression
Immunohistochemical analysis of the endometriotic lesions
28 days after implantation demonstrated increased staining
for the main proangiogenic factor VEGF in endometriotic
tissues from control rats (Figures 4A,C), which was reduced
by m(PEA/PLD) (10 mg/kg) treatment (Figures 4B,C). To
better clarify the effect of m(PEA/PLD) on endothelial cells
ICAM-1 expression was examined. Positive immunostaining
for ICAM-1 was significantly increased in the vessels of sub
mucosa and lamina propria in tissues collected from control
rats (Figures 4D,F). Treatment with m(PEA/PLD) (10 mg/kg)
reduced ICAM-1 staining (Figures 4E,F). Endometriotic lesions
exhibited an elevated accumulation of neutrophils, as assessed
by MPO activity, a reliable indicator of polymorphonuclear
cell infiltration in endometriotic lesions. A marked staining for
MPO was observed in endometriotic tissues from control rats
(Figures 4G,I), which was significantly reduced m(PEA/PLD)
(10 mg/kg) (Figures 4H,I).
Effects of m(PEA/PLD) Treatment on
IκB-α Degradation and NF-κB Activation
To investigate the cellular mechanisms by which m(PEA/PLD)
treatment may attenuate the development of endometriosis, we
analyzed IκB-α degradation and NF-κB expression by Western
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FIGURE 2 | Effect of m(PEA/PLD) treatment on Masson trichrome and MMP9 expression. Masson trichrome staining showed that tissues from the
endometriotic control group displayed fibrosis (0.66) (A,C), which was more pronounced in the m(PEA/PLD) group (3.33) (◦p = 0.01) (B,C). Positive staining for
MMP9 was significantly increased in vehicle-treated rats (6.3) (D,F), whereas m(PEA/PLD) (10 mg/kg) reduced the degree of positive staining for MMP9 in cysts
(1.33) (E,F) (◦p = 0.01). Data are means ± SD of 10 rats for each group. ◦P < 0.05 vs. vehicle group.
blot analysis. Cyst samples from control-rats showed only
low IκB-α expression compared to the m(PEA/PLD)-treated
group where IκB-α was not (Figures 5A,C). NF-κB levels in
endometriotic tissues were noticeably increased 28 days after
implantation. m(PEA/PLD) treatment significantly decreased
NF-κB levels (Figures 5B,D).
Effects of m(PEA/PLD) Treatment on
Nitrotyrosine and PAR Formation
To define the presence of nitrogen derivatives and/or
“peroxynitrite formation” in the endometriotic lesions 28 days
after implantation, immunohistochemical analysis was applied
to identify nitrotyrosine, a specific marker of nitrosative stress.
Endometriotic explants from control rats revealed positive
nitrotyrosine staining (Figures 6A,C), whereas m(PEA/PLD)
(10 mg/kg) treatment resulted in a significant reduction
(Figures 6B,C). Further, Western blot analysis revealed a
significant increase in nitrotyrosine expression (Figures 6G,H)
in control rats, which was reduced in the m(PEA/PLD) group. To
investigate poly(ADP-ribose)polymerase (PARP) activation PAR
formation was analyzed immunohistochemically. PAR staining
was significantly increased in the nuclei of inflammatory cells
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FIGURE 3 | Effect of m(PEA/PLD) treatment on mast cells and NGF expression. Toluidine blue staining revealed that mast cell numbers in the endometriotic
tissues from the m(PEA/PLD) group (4.66) (B,C) was significantly reduced compared to the control group (26.66) (A,C) (◦p = 0.01). NGF staining was significantly
increased in vehicle-treated rats (6.66) (D,F), whereas m(PEA/PLD) (10 mg/kg) reduced the extent of staining for NGF (1.33) (E,F) (◦p = 0.01). Western blot analysis
showed that NGF levels were considerably higher in samples from vehicle-treated control rats (16032.33), while m(PEA/PLD) treatment decreased NGF expression
(100) (G,H) (◦p = 0.01). Data are means ± SD of 10 rats for each group. ◦p < 0.05 vs. vehicle group.
in cyst tissues collected from control rats (Figures 6D,F), and
m(PEA/PLD) (10 mg/kg) treatment reduced this rise in PAR
staining (Figures 6E,F).
Effect of m(PEA/PLD) Treatment on Pain
Behaviors
To investigate directly the reduction of pain produced by
the m(PEA/PLD) treatment immediately after implantation we
analyzed the animals’ behaviors. The m(PEA/PLD) treated rats
showed significantly lower duration of uterine pain behaviors
than vehicle-treated control animals (Figure 7A). m(PEA/PLD)
resulted antinociceptive effect in tail-flick (Figure 7B) and hot
plate test (Figure 7C) already after 7 days of treatment (21 days
after implantation), which increased at 14 days of treatment
(28 days after implantation). Administration of vehicle had no
effect on nociceptive threshold.
DISCUSSION
Implantation, proliferation, angiogenesis, and inflammation play
a central role in the initiation and growth of endometriotic
lesions (Delbandi et al., 2013). Using an autologous rat
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FIGURE 4 | Effect of m(PEA/PLD) treatment on VEGF, ICAM and MPO expression. Positive staining for VEGF was considerably increased in cyst tissue from
vehicle-treated control rats (6.33) (A,C), m(PEA/PLD) (10 mg/kg) reduced this positive staining (2) (B,C) (◦p = 0.01). Positive staining for ICAM-1 was higher in
tissues collected from control rats (6.33) (D,F), and treatment with m(PEA/PLD) reduced this positive staining for ICAM-I (1.33) (E,F) (◦p = 0.01). Positive staining for
MPO was markedly increased in cyst tissues from vehicle-treated control rats (7.33) (G,I); m(PEA/PLD) significantly reduced polymorphonuclear cell infiltration as
MPO positive staining (1.33) (H,I) (◦p = 0.01). Data are means ± SD of 10 rats for each group. ◦p < 0.05 vs. vehicle group.
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FIGURE 5 | Effect of m(PEA/PLD) treatment on IκB-α degradation and NF-κB. Cyst samples from vehicle-treated control rats displayed low IκB-α expression
(2591.71) while m(PEA/PLD) treatment did not allow IκB-α degradation (22881.60) (A,C) (◦p = 0.03). NF-κB levels in endometriotic cyst nuclear fractions (18684.32)
were noticeably increased 28 days after implantation; m(PEA/PLD) treatment significantly decreased NF-κB levels (3567.70) (B,D) (◦p = 0.02). Data are means ± SD
of 10 rats for each group. ◦p < 0.05 vs. vehicle group.
model of surgically induced endometriosis, we show that
m(PEA/PLD) treatment brought about a significant decrease
in cyst diameter and reduced histopathological score. In this
model the degree of fibrosis is another important pathological
index (Zheng et al., 2016), and m(PEA/PLD) treatment
improved also fibrosis score in endometriotic lesions. The
adherence and invasion of endometriotic cells require an over-
production of MMPs. MMPs, a family of endoproteases, have
been suggested to be involved in basement membrane and
extracellular matrix degradation, which are crucial steps for
cellular invasion and migration. The expression of several MMPs,
especially MMP9, has been demonstrated in endometriosis
(Wu et al., 2005). Our results confirmed MMP9 up-regulation
and showed that treatment with m(PEA/PLD) significantly
reduced immunostaining of MMP9. Mast cells appear to
play an important role in the development of endometriosis
(Howard, 2009) and have been found in the implanted tissue,
proximal to nerves, and are thus well placed to release
numerous mediators, such as NGF, and thereby contribute to
endometriotic pelvic pain (Bokor et al., 2009). m(PEA/PLD)
administration decreased mast cell number in endometriotic
cysts, compared to vehicle-treated rats. This finding is in line
with reported analgesic effects of PEA. Indeed, numerous studies
have shown that PEA by the modulation of mast cells activation
controls pain perception (Bettoni et al., 2013). Treatment with
m(PEA/PLD) led to, a significant reduction of NGF expression
in endometriotic cysts paralleled the decrease in mast cell
numbers.
Mast cells play a central role in neoangiogenesis, another
endometriosis feature, which guarantees oxygen supply to lesions
(Groothuis et al., 2005). Histological analysis of endometriotic
cysts from rats receiving m(PEA/PLD) demonstrated a strong
antiangiogenic effect. Conceivably, VEGF down-regulation was
due to mast cell modulation by m(PEA/PLD). VEGF is released
by mast cells during chronic inflammation (Dmowski and Braun,
2004), and this reduced angiogenesis may be responsible for
the reduction in cyst diameter in m(PEA/PLD)-treated animals.
New vessel formation is required for delivery of nutrients and
oxygen to cysts, facilitating their implantation and development.
Increasing evidence points to a crucial role for ICAM-1 in the
pathological processes underlying endometriosis (Mousa, 2003).
Because treatment with m(PEA/PLD) reduced ICAM-1 up-
regulation, m(PEA/PLD) could reduce the interaction between
neutrophils and endothelial cells mediated by ICAM-1 at the
adhesion phase. These results are consistent with the reduced
leukocyte infiltration in endometriotic cysts indicated by MPO,
an important enzyme used by granulocytes during phagocytic
lysis of engulfed foreign particles. In endometriotic lesions
both neutrophilic and eosionophilic myeloid cell types, at all
stages of maturation, exhibit strong cytoplasmic reactivity for
MPO (Berkes et al., 2014). m(PEA/PLD) treatment decreased
MPO reactivity in endometriotic cysts, compared to vehicle-
treated rats. The protective effects of m(PEA/PLD) may be
attributable, in part, to suppression of the inflammatory
response via down-regulation of NF-kB (Esposito and Cuzzocrea,
2013). Our results confirmed that NF-kB is activated in
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FIGURE 6 | Effect of m(PEA/PLD) treatment on nitrotyrosine and PAR formation. Cyst sections from vehicle-treated control rats revealed positive staining for
nitrotyrosine (7.33) (A,C), whereas m(PEA/PLD) (10 mg/kg) reduced this staining (1.66) (B,C) (◦p = 0.01). Western blot analysis (G,H) revealed a significant elevation
in nitrotyrosine expression in vehicle-treated control rats (36526.59) while m(PEA/PLD) reduced its expression (100) (◦p = 0.04). Positive staining for PAR was clearly
increased in nuclei of inflammatory cells in cyst tissues from vehicle-treated control rats (6.66) (D,F), while m(PEA/PLD) reduced such staining (1) (E,F) (◦p = 0.01).
Data are means ± SD of 10 rats for each group. ◦p < 0.05 vs. vehicle group.
endometriotic cysts of rats, an effect significantly reduced by
m(PEA/PLD) administration. m(PEA/PLD), by reducing NFkB
translocation in the nucleus, decreased the phosphorylation of
IkBα. This result indicated that m(PEA/PLD) is able to control
oxidant/antioxidant balance.
Endometriotic lesions involve an over-production of
ROS, which cause oxidation of cellular components such
as proteins, lipids, and DNA, resulting in cell damage. The
most common ROS are superoxide anion and peroxynitrite.
Cellular targets of peroxynitrite include carbohydrates, proteins,
lipids, and nucleic acids, whose reaction of peroxynitrite
results in protein modification by oxidization of sulfhydryl
groups, lipid peroxidation and nitration of tyrosine residues.
Lipid peroxidation and nitrotyrosine formation were elevated
in endometriotic tissues, and treatment with m(PEA/PLD)
significantly reduced immunostaining of nitrotyrosine.
Peroxynitrite can activate PARP, a DNA repair enzyme that
responds to single-strand breaks in DNA by synthesizing
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FIGURE 7 | Effect of m(PEA/PLD) treatment on pain behaviors. Animals
treated with m(PEA/PLD) displayed less pain behaviors than vehicle-treated
control rats. The baseline nociception and the antinociceptive effect after
m(PEA/PLD) administration were measured looking at the uterine pain
behaviors (A), with the tail-flick method (B) and the hot plate method (C).
Vehicle-treated control rats were affected by longer uterine crises than
m(PEA/PLD) treated rats (A) (◦p = 0.010). During the tail-flick (B) and hot
plate (C) tests animals administrated with m(PEA/PLD) showed a significant
antinociceptive effect compared to the vehicle-treated control rats
(◦p = 0.004). Data are means ± SD of 10 rats for each group. ◦p < 0.05 vs.
vehicle group.
chains of ADP-ribose that serve as an indicator for other
enzymes of DNA repair. As NAD+ is an obligate substrate to
in the production of ADP-ribose monomers, hyper-activation
of PARP can deplete cellular reserves of NAD+ and lead
to ATP depletion. Depletion of ATP and NAD caused by
this activation leads to cellular dysfunction and death. In
the present study, m(PEA/PLD) decreased PARP activity in
endometriotic cysts. One needs to keep in mind that apoptosis
plays a key role in the endometriotic process (Wang et al.,
2016).
It has been demonstrated that the PEA–PLD combination
seems to be very useful in controlling chronic pelvic pain
associated with endometriosis (Giamberardino et al., 2010;
Indraccolo and Barbieri, 2010). In agreement with previous
results, in our study we showed that m(PEA/PLD) treatment,
compared with vehicle, significantly reduced the behavioral
indicated of uterine pain and animals showing no signs of chronic
suffering.
Palmitoylethanolamide has been explored in man in various
clinical trials in a variety of pain states, for inflammatory and pain
syndromes (Indraccolo and Barbieri, 2010). PEA is available for
human use as a supplement and as food for medical purposes.
Our data clearly demonstrate that treatment with
m(PEA/PLD) reduced the inflammatory process and pain
associated with an experimental rat model of surgically induced
endometriosis. Thus we propose that the m(PEA/PLD) as
witnessed for the assessment of pain, can enter into a clinical
study to verify the effectiveness of this treatment in controlling
the inflammatory process associated with endometriosis in
woman.
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